STUDresearch · Peptide
Humanin
Also known as
HN · mitochondrial-derived peptide humanin · MDP humanin · MT-RNR2 peptide · MTRNR2-encoded peptide · HNG (S14G-humanin analog) · S14G-HN · S14G-humanin · Humanin-G · HNGF6A · Colivelin (related potent derivative) · MAPRGFSCLLLLTSEIDLPVKRRA
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Some talk
Systemic
SubQ
Mitochondrial & metabolic peptides
Systemic — circulating mitochondrial-derived signal with multi-organ research interest (brain, heart, pancreas/islets, endothelium, skeletal muscle, retina).
What people say
Humanin is an endogenous mitochondrial-derived peptide; HNG is a more potent S14G analog and must not be treated as the same exposure. Exogenous human therapeutic efficacy, dose and safety are not established.
Doses people talk about
Rows record observed amounts only. No human dose-finding trial establishes a therapeutic range, and animal mg/kg exposures are not converted into human instructions.
How it may feel
The inspected reports are too sparse for a typical trajectory: possible anxiety or sleep changes, null effects, contradictory exposure history, and a confounded long post-stop impression all appear.
Single native-Humanin report500 mcg once
The poster suspected placebo behind a possible anxiety change.
One-week report2 mg every other day
One user linked sleep-through-night to the second exposure; product identity was not verified.
Combined-dose report5 mg Humanin plus 5 mg MOTS-c
Initial null report, later possible sleep change with Epitalon co-use, and contradictory same-author exposure history.
Weekly combined report5 mg Humanin weekly with MOTS-c
Unverified identity and no Humanin-only attribution.
Half-life & effect duration
- Half-life in the body
- Native HumaninNo settled estimate
- HNG analog · abdominal injection · miceAbout 30 minutes
- HNG analog · abdominal injection · ratsOver 4 hours
- Felt duration people report
- AccountsPossible anxiety or sleep change, or no effect
- After sequential peptide coursesLonger-lasting impressions reported; no consistent Humanin-only duration
Cycles people discuss
Community notes describe 4–12-week or longer blocks and both daily and multi-weekly use, but these patterns are not trial-validated. Introducing several mitochondrial peptides in sequence makes cycle attribution weaker.
Timing
Morning use appears in community charts, while some describe an AM/PM split. Empty-stomach claims are unproven; these habits are not an established schedule shared by native Humanin and its analogs.
Stacks
Example stack math (charts only): Some longevity tables list HNG ~0.5–1 mg/day beside MOTS-c ~5–10 mg (often not daily — MOTS-c weekly culture differs); always verify each compound’s own schedule.
Watch for
No therapeutic human AE dataset: Side-effect frequencies from RCTs of exogenous HN/HNG supplementation are not established; ADDF-style reviews stress unknown therapeutic utility and unestablished clinical dosing.
Tap a line for the full notes and source context.
Timing context & sources
Half-life in the body
A human bodily half-life for exogenous native Humanin was not established.
Primary rodent research instead measured the HNG analog after IP administration: about 30 minutes apparent half-life in wild-type male mice and over 4 hours in male rats, with analog- and IGFBP-3-dependent differences.
Different molecule, animal species, sex and intraperitoneal route. These findings cannot be relabeled as native-Humanin human or subcutaneous PK.
- Chin et al. — Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents (opens in a new tab)PubMed abstract and indexed full-text extract: intraperitoneal HNG/HNGF6A in male wild-type and IGFBP-3-knockout mice; HNG half-life in wild-type mice was about 30 minutes, while HNGF6A and HNG in knockout mice persisted longer. The male Sprague-Dawley rat IP HNG dose is reported as 4 mg/kg in Figures 5–6 captions and 5 mg/kg in Methods and Discussion; apparent half-life exceeded 4 hours, with plasma and liver detection but no brain or heart detection at the tested times.Rodent intraperitoneal PK of specific analogs, not native-humanin therapeutic PK in humans and not subcutaneous community products. The direct PMC page presented a browser-check screen, so review used PubMed plus its indexed article content and figures.
Felt duration people report
No reproducible felt-duration window was established for native Humanin or an identity-verified Humanin-only product.
Reports include a single 500 mcg native-Humanin exposure with suspected placebo, a short sleep report, null effects, and a long post-stop impression after sequential SS-31, MOTS-c and Humanin.
Tiny anonymous sample, uncertain product identity, combined or sequential agents, contradictory same-author history, no blinding, and recalled schedules. Subjective persistence cannot be used as a PK surrogate.
- Reddit r/Peptides — MOTS-c, Humanin, Ipamorelin and Mod-GRF stack discussion (opens in a new tab)Post and same-author replies: a few combined 5 mg Humanin plus 5 mg MOTS-c doses were initially described as producing no difference, followed by possible sleep change while 1 mg nightly Epitalon was also used; a later comment by the same author said the stored Humanin had never been tried. Another commenter reported 2 mg every other day for one week and sleeping through the night after the second exposure.Sparse, anonymous, unverified products and a combined stack. The same-author chronology is internally contradictory, and Epitalon/MOTS-c co-use prevents isolating Humanin. The separate 2 mg report has only one week of observation.
- Reddit r/Peptides — Humanin stability and early experience discussion (opens in a new tab)Post and visible replies: the OP specified native Humanin rather than HNG and described one 500 mcg exposure with possible anxiety reduction while explicitly suspecting placebo. Another commenter reported 5 mg Humanin weekly with MOTS-c. A 25–50 mcg figure was admitted to have been copied from another post.Anonymous, unverified products with uncertain storage and molecule identity. One-exposure impressions and copied numbers do not establish efficacy, stability, common dosing, or felt duration. Preparation details are intentionally not reproduced.
- Reddit r/Peptides — Humanin experiences (opens in a new tab)Visible replies: one user reported no perceptible short- or medium-term effects and said long-term effects were unknown; another interested participant had not used it and described dose, timing and duration as complete unknowns.Very small anonymous discussion, unverified identity and no controlled outcomes. Statements by non-users are evidence of uncertainty, not exposure evidence.
- Reddit r/PeptideForum — SS-31 and anti-aging sequence discussion (opens in a new tab)Visible first-person reply describing sequential SS-31, then MOTS-c, then Humanin use and feeling locked in, with perceived benefit still present about two months after stopping. The same author could not recall the exact cycle and said their usual cycles were six to eight weeks.Anonymous retrospective sequence with unverified products and no washout between agents. The long post-stop impression cannot be assigned to Humanin, distinguished from the prior peptides, or interpreted as plasma persistence.
What people say
- Subjective energy / resilience: Sparse community and small app-log samples mention steadier energy or “resilience,” often inside multi-peptide stacks — confounded and not a stimulant feel. anecdote
- vs SS-31: SS-31 (elamipretide-class) is cardiolipin/ETC membrane-targeted; humanin is a secreted survival signal — different mechanisms, sometimes co-run in “mito stacks.” forum
- Stack halo warning: Longevity stacks (HNG + MOTS-c + NAD axis ± SS-31 ± epitalon) make single-agent credit unreliable. forum
- Neuroprotection (founding claim): Cell models show rescue from Aβ toxicity, FAD gene insults, oxidative stress, and apoptosis markers; HN discovered as a neuronal survival factor. lab
- AD / cognitive models: Chronic HNG (e.g. ~0.1 μg IP every other day for months in APP/PS1; 50–100 μg/kg IP regimens) reduced plaque burden / inflammation markers and improved spatial memory in some rodent studies; intranasal HNG and colivelin also used in AD models. animal
- Cognitive aging / midlife treatment: Midlife or aged-mouse HNG regimens reported to slow some cognitive and motor decline metrics and improve healthspan-linked outcomes without always extending maximum lifespan. animal
- Lifespan biology (preclinical/observational): C. elegans humanin overexpression extended lifespan in a daf-16/FOXO-dependent manner; mouse HNG late-life biweekly IP improved healthspan measures more clearly than lifespan in key papers; naked mole rats show relatively stable circulating humanin with age in comparative work. animal
- Centenarian / family signal: Children of centenarians have been reported to carry higher circulating humanin than age-matched controls in longevity cohorts — observational, not proof that injecting HNG recreates that phenotype. trial
- Age decline narrative: Circulating humanin often falls with age in mice, monkeys, and humans in multiple reports (magnitude varies by study/assay); some mitokine cohorts also report complex age patterns, so “always down with age” is not universal across every paper. trial
- Insulin / metabolism: Improved hepatic and peripheral insulin sensitivity and beta-cell survival under stress in animals; HNGF6A especially framed for insulin action / GSIS because it avoids IGFBP-3 binding. animal
- Heart / ischemia–reperfusion: HNG reduced infarct size and improved functional metrics in rodent models and in a minipig reperfusion study (e.g. ~2 mg/kg near reperfusion in pigs; multi-μg/kg IV and multi-mg/kg intracardiac mouse protocols in literature). animal
- Stroke / brain ischemia models: HNG or colivelin pretreatment reduced infarct volume and neurological deficits in MCAO-type models (ICV and peripheral routes both appear). animal
- Endothelium / atherosclerosis interest: Lower circulating humanin associated with coronary endothelial dysfunction in human observational data; HNGF6A preserved endothelial NO-related markers in high-cholesterol ApoE mice. trial
- Cytoprotection / bioenergetics: In-vitro and ex-vivo work shows anti-apoptotic signaling, preserved mitochondrial membrane potential under stress, and increased basal OCR / reserve capacity talk. lab
- Retina / AMD models: HNG restored viability in cybrid models using mitochondria from AMD patients via reduced Bax-mediated apoptosis and JAK2 survival signaling. lab
- Germ-cell / chemo-adjunct models: Potent HNG protected normal germ cells and leukocytes from chemotherapy toxicity in some preclinical designs without always blocking anti-tumor efficacy — still model-specific. animal
- Hair / bone side-interest: HNG promoted hair-shaft elongation in organ culture and topical mouse models; HNGF6A promoted osteoblast differentiation in cell culture — not primary community use cases. animal
- vs MOTS-c (bro framing): Humanin = cytoprotective / neuro / anti-apoptotic / healthspan signaling; MOTS-c = exercise-mimetic metabolic / AMPK / fat-loss training narrative. Often stacked as complementary MDPs. forum
Doses people talk about
- Amounts actually found in forum accounts: 500 mcg native Humanin once; 2 mg every other day for one week; 5 mg Humanin plus 5 mg MOTS-c in combined logs; and 5 mg weekly with MOTS-c. Identity was often unverified, so these are observations, not a dominant dose. forum
- Conservative microgram band: ~100–300 mcg SC daily appears as a cautious starter figure on some guides (sometimes 200–300 mcg). forum
- Mid “research protocol” band: ~500–750 mcg HNG SC daily (sometimes split AM/PM) on community ladders between micro and full-mg use. forum
- Advanced daily band: ~1–2 mg HNG SC daily in more aggressive charts; PeptIQ-style tiny self-report samples also cluster around 1–2+ mg per injection — small-n and selection-biased. forum
- Weekly split pattern (alternate camp): ~1–5 mg total per week HNG SC, split across 2–3 injections (e.g. multi-mg pins a few times weekly rather than daily). Starting talk near ~1 mg/week appears on some calculators. forum
- 2–5×/week multi-mg camp: Peptide-review writeups describe ~1–5 mg HNG SC (or experimental IN) two to five times weekly as another extrapolation style from animal work. forum
- Titration talk: Common chart pattern is start ~0.5 mg HNG daily week 1, then advance toward ~1–2 mg if tolerated — still empirical, not PK-guided. forum
- Morning timing preference: AM SC is the default in many charts; empty-stomach claims are unproven. Short plasma half-life drives frequent (daily or multi-weekly) schedules more than clock-time dogma. forum
- Not oral: Peptides are GI-labile; oral “humanin capsules” are not the research or community standard route. forum
- Purity / identity risk: Without third-party testing, labeled mcg/mg and HN vs HNG identity may not match delivered peptide — structural gray-market risk. forum
- Analog first rule: Most community protocols assume HNG (S14G). Native HN is ~1000× weaker in classic potency assays; do not treat “1 mg humanin” and “1 mg HNG” as interchangeable without knowing which molecule is in the vial. trial
- Intranasal research note: Intranasal HNG and especially colivelin appear in AD-model literature; community IN humanin talk exists but is thinner and less standardized than SC. trial
- HNGF6A / colivelin caveat: Metabolic papers using HNGF6A and neuro papers using colivelin (fM–pM potency class) cannot be copied onto gray-market HNG milligram charts. trial
- Framing: All figures are research/community discussion only — not medical advice, not prescriptions. There is no trial-validated human therapeutic dose for exogenous humanin or HNG. forum
- Animal dose mismatch (do not 1:1 scale): Examples from literature include HNG ~4 mg/kg IP biweekly for midlife/old-mouse healthspan work; ~0.1 μg IP every other day for months in APP/PS1; 50–100 μg/kg IP in AD insulin-sensitivity models; pig ~2 mg/kg near reperfusion; rat ~252 μg/kg IV during ischemia; various ICV microgram and nanomolar CNS doses. These are model tools, not human charts. animal
How it may feel
- Immediate evidence is sparse: One native-Humanin user reported possible anxiety reduction after a single 500 mcg exposure but suspected placebo; another discussion found no perceptible short-term effect. forum
- First week: One commenter reported sleeping through the night after the second 2 mg every-other-day exposure; another stacked account initially reported no change and later contradicted whether Humanin had been used. forum
- What users actually describe: Possible sleep or anxiety changes and null effects, not a consistent energy or clarity pattern. MOTS-c and Epitalon co-use make the positive reports especially hard to assign. forum
- Weeks 3–4: Common first reassess window — keep, drop, or question whether the vial is HN vs HNG, purity, or dose math. forum
- Weeks 4–8: Gradual well-being, metabolic ease, or cognitive “edge” talk when present; still not a sharp on-switch like stimulants or some GH secretagogues. anecdote
- Months 2–3: Longevity-style users may continue open-ended or finish an 8–12 week block; logging thins out and attribution gets worse. forum
- After stop is unresolved: A sequential SS-31→MOTS-c→Humanin user recalled feeling benefit about two months after stopping but could not recall the exact cycle. This cannot isolate Humanin or establish a washout clock. forum
- Reddit stack anecdote (sparse): At least one multi-peptide thread reported adding multi-mg humanin to MOTS-c without noticing extra difference beyond MOTS-c alone — illustrative of how hard isolation is, not a controlled null. anecdote
Cycles people discuss
- Common research-use block: ~8–12 weeks on is the most repeated community cycle length for longevity / metabolic / neuro interest. forum
- Off periods: ~4–8 weeks off after a multi-month block appears as a conservative precaution when long-term human safety data are absent; not evidence-based necessity. forum
- Shorter pulses: ~4–6 week looks still appear when users are testing tolerance or stacking with other mito agents. forum
- Extended / open-ended use: Some longevity logs run multi-month or continuous healthspan-style use because endogenous levels are continuous; safety data for chronic exogenous HNG are lacking. forum
- Daily vs multi-weekly: Both daily SC and 2–5×/week schedules are discussed; choice is culture/convenience more than comparative trials. forum
- Pulse vs maintain: No validated load→maintain clinical scheme; animal biweekly IP healthspan regimens inspire some intermittent human charts. forum
- Re-runs: Seasonal or yearly restarts are described; long-term gray-market surveillance is sparse. forum
- Stack sequencing: Community writeups often introduce HNG alone for 1–2 weeks before adding MOTS-c / SS-31 / NAD agents so sides and feel can be attributed. forum
Timing
- Why frequent dosing talk: Short plasma residence is the usual justification for daily or multi-times-weekly SC schedules despite intermittent animal benefits. forum
- Male-mouse analog PK: After intraperitoneal HNG, apparent circulating half-life in wild-type mice was about 30 minutes; this is an HNG animal result, not native-Humanin human PK. animal
- Male-rat analog PK: In this intraperitoneal HNG experiment, the paper reports the dose inconsistently: 4 mg/kg in figure captions and 5 mg/kg in Methods and Discussion. Apparent half-life exceeded 4 hours; plasma and liver were detected, while brain and heart were not. This is not a human or SC estimate. animal
- IGFBP-3 clearance link: Binding to IGFBP-3 influences clearance; HNGF6A (F6A, non-IGFBP-3-binding) is framed as having superior stability / distinct PK versus IGFBP-3-binding analogs. trial
- Tissue vs plasma: Preclinical benefits after intermittent dosing suggest downstream signaling and tissue effects can outlast measurable plasma levels — mechanism, not a human dosing proof. trial
- Receptor cascade timing: JAK2/STAT3, Akt, ERK and related survival pathways are the “downstream feel” story; users should not equate blood presence with ongoing intracellular protection. trial
- No human PK package: Published human therapeutic PK/PD for exogenous HNG/HN supplementation is essentially absent; any “2–4 hour half-life” human-facing claim is usually rodent-derived extrapolation. trial
- Exercise angle: Acute exercise can raise circulating humanin in human interventional/biomarker studies — context for endogenous dynamics, not a dosing schedule. trial
More on what it is
- Research lens: Always match the chart to native HN vs HNG vs HNGF6A vs colivelin; mcg vs mg mix-ups and HN/HNG mislabeling are recurring gray-market risks. forum
- What it is: Endogenous mitochondrial-derived peptide (MDP) encoded by a short open reading frame in mtDNA 16S rRNA (MT-RNR2). Length depends on translation compartment: ~21 aa if mitochondrial translation, ~24 aa if cytoplasmic (common research sequence MAPRGFSCLLLLTSEIDLPVKRRA). Research chemical / not an approved drug. trial
- Discovery story: First reported 2001 (Hashimoto / Nishimoto lab) from a cDNA screen of relatively spared occipital cortex of an Alzheimer’s patient — identified as a factor that rescued neurons from Aβ and familial-AD gene insults. Independently linked soon after to IGFBP-3 and Bax binding. trial
- Why people care: Longevity and “mito healthspan” umbrella — circulating humanin often declines with age across species, centenarian-offspring cohorts show higher levels in some studies, and preclinical models span neuroprotection, insulin action, cardiac ischemia, and cell survival under stress. trial
- HNG vs native: Community and most modern preclinical work use HNG (S14G-humanin), a single Ser→Gly swap at position 14 that is repeatedly described as ~1000× more potent at the humanin receptor / neuroprotection assays than native HN. Vendor “Humanin” vials are often HNG — label-check is mandatory. trial
- Mechanism (simplified): Intracellular anti-apoptosis via Bax / Bid-family partners; extracellular survival via the CNTFRα–WSX-1–gp130 tripartite receptor → JAK2/STAT3 (plus ERK/Akt context effects) and FPRL1/FPR2 talk; IGFBP-3 binding modulates survival and IGF-axis clearance. trial
- Evidence bar: Dense cell and animal literature; human data are mostly observational biomarkers (levels vs age/disease/centenarian family status) and exercise-response papers — no established therapeutic human dose or approved indication for exogenous HN/HNG. trial
- Other analogs (do not swap charts): HNGF6A adds F6A so it does not bind IGFBP-3 (altered PK / stronger insulin-action framing); colivelin is a more distant ADNF-fusion derivative active at fM–pM ranges in models and is not the same product as HNG. trial
Stacks
- Example stack math (charts only): Some longevity tables list HNG ~0.5–1 mg/day beside MOTS-c ~5–10 mg (often not daily — MOTS-c weekly culture differs); always verify each compound’s own schedule. forum
- Mito membrane + signal: HNG + SS-31 (elamipretide-class) for “ETC membrane repair + survival signaling” narrative. forum
- NAD axis: HNG with NMN, NR, or injectable NAD+ in aging-energy stacks — attribution nearly impossible. forum
- Epitalon / pineal longevity combos: Occasional multi-pathway longevity stacks; pure marketing adjacency risk. forum
- Senolytic adjacency: Rare FOXO4-DRI + HNG “clearance + protection” lore on vendor blogs — very thin evidence and high confound. forum
- GH secretagogue neighborhood: Older forum posts combine MOTS-c / humanin with ipamorelin or mod-GRF — note endogenous humanin is often inverse to GH/IGF-1 biology, so stacking logic is debated not settled. forum
- GLP-1 adjacency: Modern logs sometimes run mito peptides beside retatrutide or other incretins; metabolic outcomes cannot be credited to humanin alone. anecdote
- Lifestyle baseline: Sleep, resistance training, aerobic work, and metabolic hygiene are frequently what actually moves subjective scores in longevity stacks. forum
- Core MDP pair: Humanin/HNG + MOTS-c — cytoprotective/neuro framing + metabolic/exercise-mimetic framing; one sparse forum log used multi-mg of each and credited MOTS-c more for fat-loss feel. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Redness, irritation, itch, or mild SC pain are the most common practical downsides in community reports. forum
- Generally quiet systemic profile (anecdotal): Community writeups often call 0.5–2 mg HNG daily “well tolerated,” with occasional mild transient fatigue — tiny samples, no controlled AE tables. forum
- Pregnancy / lactation: No safety data; community protocols exclude these populations. forum
- Source / identity risks: Mislabel HN vs HNG, contamination, underdosed vials, and mcg/mg math errors are structural gray-market hazards — HNG’s potency amplifies dose-error consequence relative to native HN. forum
- Dose-chaos risk: Charts span ~100 mcg/day to multi-mg/day and weekly multi-mg splits; unit conversion mistakes are easy. forum
- Not risk-free: Research-chemical status + no approved dose + thin long-term exogenous safety data + anti-apoptotic mechanism debate. forum
- No therapeutic human AE dataset: Side-effect frequencies from RCTs of exogenous HN/HNG supplementation are not established; ADDF-style reviews stress unknown therapeutic utility and unestablished clinical dosing. trial
- Anti-apoptosis / malignancy debate: Because humanin activates survival pathways (STAT3, Akt, ERK) and blocks Bax-driven death, community and scientific commentary flag theoretical concern in active or high-risk malignancy. Preclinical cancer data are mixed (context- and tumor-type dependent): some models show chemo-protection of healthy tissue without blocking anti-tumor effect; others raise progression concern. Not a quantified human risk number. trial
- Context- and sex-dependent biology: Reviews note effects can be context- and sex-dependent; endogenous physiology ≠ high-dose exogenous HNG. trial
- IGF-axis interactions: Humanin levels often inverse to GH/IGF-1; HN binds IGFBP-3 and can lower circulating IGF-1 in models. Stacks with GH, GHRHs, IGF-1, or strong IGF-axis drugs are pharmacologically uncharted for exogenous HNG. trial
- Metabolic monitoring talk: Improved insulin-sensitivity framing leads some diabetes-interested users to watch glucose when stacking metabolic agents — precaution lore, not a labeled interaction study. forum
- Senescence complexity: MDP effects on senescence/SASP are reported as potentially mixed and cell-type dependent in the literature — another reason chronic high-dose use is not “free.” trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.